Nanorobotics
Nanorobots for Targeting and Destroying Cancer Cells
Company Overview
Snapshot
Founded in May 2019 by Yossi Keret, Nanorobotics operates with 1–10 employees. The company is in the Pre-Funding stage and holds one patent. In November 2024, Nanorobotics ceased to operate.
Business overview
Nanorobotics is a preclinical-stage startup focused on cancer eradication through its patented light-activated nanomolecular platform technology. The company develops molecular therapies leveraging Molecular Nanomachines (MNMs) that mechanically drill through cell membranes, targeting cancers resistant to conventional treatments. Its leading molecule, MNM96, is designed for efficacy and safety, with plans to advance to human clinical trials. Nanorobotics operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals, Oncology, and Biotechnology.
Log in to access full profile ›Company Intelligence Q&A
- What is Nanorobotics' primary mission?
- Nanorobotics aims to eradicate cancer using its patented light-activated nanomolecular platform technology.
- What is the core technology developed by Nanorobotics?
- Nanorobotics utilizes Molecular Nanomachines (MNMs) that mechanically drill through cell membranes to deliver molecular therapies.
- What is MNM96?
- MNM96 is Nanorobotics' leading molecule, which has shown preclinical efficacy and safety, positioning it for human clinical trials.
- When was Nanorobotics founded?
- Nanorobotics was founded in May 2019.
- What is the current operational status of Nanorobotics?
- Nanorobotics ceased to operate in November 2024.